Načítá se...
Precision medicine becomes reality—tumor type-agnostic therapy
Precision medicine just witnessed two breakthroughs in oncology in 2017. Pembrolizumab (Keytruda), Merck’s anti-programmed cell death-1 (PD-1) monoclonal antibody (mAb), received accelerated approval in May 2017 by the US Food and Drug Administration for the treatment of adult and pediatric patients...
Uloženo v:
| Vydáno v: | Cancer Commun (Lond) |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5953403/ https://ncbi.nlm.nih.gov/pubmed/29764494 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40880-018-0274-3 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|